טוען...
Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...
שמור ב:
| הוצא לאור ב: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
D.A. Spandidos
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/ https://ncbi.nlm.nih.gov/pubmed/28927109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|